相关实验视频

Updated: Jan 15, 2026

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay

Published on: February 28, 2025

通过基于结构的虚拟查发现一种共价小分子eEF1A1抑制剂

Yangping Deng¹, Sizheng Li¹, Liang Wang¹

¹College of Chemistry, State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for New Organic Matter, Nankai University, 94 Weijin Road, Tianjin 300071, China.

Journal of chemical information and modeling

|January 13, 2026

概括

研究人员确定了AKOS-04,一种针对真核细胞翻译延长因子1α1 (eEF1A1) 的新型共价抑制剂,显示了胰腺癌治疗的前景. 这一发现突出了开发新胰腺癌药物的计算方法.

科学领域:

生物化学生物化学
分子生物学分子生物学
计算化学计算化学

背景情况:

胰腺癌由于晚期诊断和有限的治疗选择而带来了重大治疗挑战.
细胞翻译延长因子1α1 (eEF1A1) 是胰腺癌治疗的有希望的标,但缺乏合理的药物设计方法.

研究的目的:

通过基于结构的虚拟查 (SBVS) 识别eEF1A1的新型小分子共价抑制剂.
为验证已识别的胰腺癌治疗抑制剂的疗效和作用机制.

主要方法:

微秒级分子动力学 (MD) 模拟以确定适合SBVS的eEF1A1构造.
基于结构的虚拟选 (SBVS) 管道针对eEF1A1 Cys234.4.
细胞热转移试验 (CETSA),滴二醇 (DTT) 和乙胺 (IAM) 治疗以确认共价结合.
变异性研究和微量热泳 (MST) 以验证化合物结合并确定关键残留物.

主要成果:

AKOS-04被确定为eEF1A1的强有力的共价抑制剂,具有纳米分子强度 (IC50 = 28.5 ± 2.86 nM).
在Cys234.4中确认了AKOS-04和eEF1A1之间的共价相互作用.
结构修改证实了烯胺双键对共价结合的必要性.
MD模拟和能量分析确定了lys84,arg218和glu230作为AKOS-04结合的关键残留物.

结论:

AKOS-04是eEF1A1向胰腺癌治疗的有前途的化合物.
针对eEF1A1 Cys234的SBVS是共价药物发现的有效策略.
计算方法显著推动了胰腺癌新型治疗方法的开发.

更多相关视频

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Published on: May 29, 2021

Fluorescence-Based Detection of FEN1 Nuclease Activity and Screening of Small-Molecule Inhibitors

Fluorescence-Based Detection of FEN1 Nuclease Activity and Screening of Small-Molecule Inhibitors

Published on: June 27, 2025

相关概念视频

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...